EVAX Earnings

EVAX reported its FY2025Q4 earnings on 2026-03-05, showcasing a revenue of against an estimate of 7.54M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following EVAX's FY2025Q4 earnings announcement on 2026-03-05, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, EVAX's stock price tends to shift by an average of -2.5% in the 10 days leading up to earnings and -4.19% in the 10 days following, providing insight into potential market.

For 2025/Q3, analysts estimate EVAX's annual revenue to reach 2.50M, while the EPS is projected at -0.01. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between EVAX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, EVAX's stock price typically moves by -2.5% in the 10 days before its earnings and -4.19% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of -0.01 and revenue of 2.50M.

The earnings call highlights positive financial performance with a cash runway extended to 2027 and revenue from MSD. Significant progress in R&D, particularly in oncology and infectious diseases, enhances the company's growth prospects. While there are potential risks in partnerships and production, the overall sentiment is positive, supported by optimistic guidance and ongoing partnership discussions. The Q&A section reveals strong interest in the company's pipeline and technology, further boosting confidence. Despite some uncertainties, the overall outlook is positive, suggesting a potential stock price increase of 2% to 8%.